225 related articles for article (PubMed ID: 35396969)
1. Synthesis, preclinical evaluation, and first-in-human study of Al
Wu Y; Zhang X; Zhou H; Xu B; Tian J; Sun S; Zhang J
Eur J Nucl Med Mol Imaging; 2022 Jul; 49(8):2774-2785. PubMed ID: 35396969
[TBL] [Abstract][Full Text] [Related]
2. Preclinical Evaluation and Pilot Clinical Study of Al
Liu T; Liu C; Xu X; Liu F; Guo X; Li N; Wang X; Yang J; Yang X; Zhu H; Yang Z
J Nucl Med; 2019 Sep; 60(9):1284-1292. PubMed ID: 30796170
[TBL] [Abstract][Full Text] [Related]
3. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
4.
Lee BS; Chu SY; Jung WJ; Jeong HJ; Lee K; Kim MH; Kim MH; Chi DY; Ahn H; Lee YJ; Lee KC; Lim SM
Prostate; 2020 Dec; 80(16):1383-1393. PubMed ID: 32960990
[TBL] [Abstract][Full Text] [Related]
5. High in-vivo stability in preclinical and first-in-human experiments with [
Qin X; Guo X; Liu T; Li L; Zhou N; Ma X; Meng X; Liu J; Zhu H; Jia B; Yang Z
Eur J Nucl Med Mol Imaging; 2023 Jan; 50(2):302-313. PubMed ID: 36129493
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and pre-clinical evaluation of a new class of high-affinity
Kelly J; Amor-Coarasa A; Nikolopoulou A; Kim D; Williams C; Ponnala S; Babich JW
Eur J Nucl Med Mol Imaging; 2017 Apr; 44(4):647-661. PubMed ID: 27847991
[TBL] [Abstract][Full Text] [Related]
7. Biodistribution of [(68)Ga]PSMA-HBED-CC in Patients with Prostate Cancer: Characterization of Uptake in Normal Organs and Tumour Lesions.
Prasad V; Steffen IG; Diederichs G; Makowski MR; Wust P; Brenner W
Mol Imaging Biol; 2016 Jun; 18(3):428-36. PubMed ID: 27038316
[TBL] [Abstract][Full Text] [Related]
8. F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients.
Giesel FL; Hadaschik B; Cardinale J; Radtke J; Vinsensia M; Lehnert W; Kesch C; Tolstov Y; Singer S; Grabe N; Duensing S; Schäfer M; Neels OC; Mier W; Haberkorn U; Kopka K; Kratochwil C
Eur J Nucl Med Mol Imaging; 2017 Apr; 44(4):678-688. PubMed ID: 27889802
[TBL] [Abstract][Full Text] [Related]
9. Biodistribution and radiation dosimetry of [
Hohberg M; Kobe C; Krapf P; Täger P; Hammes J; Dietlein F; Zlatopolskiy BD; Endepols H; Wild M; Neubauer S; Heidenreich A; Neumaier B; Drzezga A; Dietlein M
EJNMMI Res; 2019 Jul; 9(1):66. PubMed ID: 31346821
[TBL] [Abstract][Full Text] [Related]
10. Intraindividual Comparison of
Giesel FL; Will L; Lawal I; Lengana T; Kratochwil C; Vorster M; Neels O; Reyneke F; Haberkon U; Kopka K; Sathekge M
J Nucl Med; 2018 Jul; 59(7):1076-1080. PubMed ID: 29269569
[TBL] [Abstract][Full Text] [Related]
11. First-in-human study of PSMA-targeting agent, [
Zhao R; Ke M; Lv J; Liu S; Liu Y; Zhang J; Xu L; Gu D; Li M; Cai C; Liu Y; Zeng G; Alexoff D; Ploessl K; Zhu L; Kung HF; Wang X
Eur J Nucl Med Mol Imaging; 2024 May; 51(6):1753-1762. PubMed ID: 38212531
[TBL] [Abstract][Full Text] [Related]
12.
Uprimny C; Kroiss AS; Decristoforo C; Fritz J; von Guggenberg E; Kendler D; Scarpa L; di Santo G; Roig LG; Maffey-Steffan J; Horninger W; Virgolini IJ
Eur J Nucl Med Mol Imaging; 2017 Jun; 44(6):941-949. PubMed ID: 28138747
[TBL] [Abstract][Full Text] [Related]
13.
Mena E; Lindenberg ML; Turkbey IB; Shih JH; Harmon SA; Lim I; Lin F; Adler S; Eclarinal P; McKinney YL; Citrin D; Dahut W; Wood BJ; Krishnasamy V; Chang R; Levy E; Merino M; Pinto P; Eary JF; Choyke PL
J Nucl Med; 2020 Jun; 61(6):881-889. PubMed ID: 31676732
[TBL] [Abstract][Full Text] [Related]
14. Preclinical evaluation of 86Y-labeled inhibitors of prostate-specific membrane antigen for dosimetry estimates.
Banerjee SR; Foss CA; Pullambhatla M; Wang Y; Srinivasan S; Hobbs RF; Baidoo KE; Brechbiel MW; Nimmagadda S; Mease RC; Sgouros G; Pomper MG
J Nucl Med; 2015 Apr; 56(4):628-34. PubMed ID: 25722448
[TBL] [Abstract][Full Text] [Related]
15. 2-(3-{1-Carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer.
Chen Y; Pullambhatla M; Foss CA; Byun Y; Nimmagadda S; Senthamizhchelvan S; Sgouros G; Mease RC; Pomper MG
Clin Cancer Res; 2011 Dec; 17(24):7645-53. PubMed ID: 22042970
[TBL] [Abstract][Full Text] [Related]
16. PSMA-Based [(18)F]DCFPyL PET/CT Is Superior to Conventional Imaging for Lesion Detection in Patients with Metastatic Prostate Cancer.
Rowe SP; Macura KJ; Mena E; Blackford AL; Nadal R; Antonarakis ES; Eisenberger M; Carducci M; Fan H; Dannals RF; Chen Y; Mease RC; Szabo Z; Pomper MG; Cho SY
Mol Imaging Biol; 2016 Jun; 18(3):411-9. PubMed ID: 27080322
[TBL] [Abstract][Full Text] [Related]
17. Combined model-based and patient-specific dosimetry for
Plyku D; Mena E; Rowe SP; Lodge MA; Szabo Z; Cho SY; Pomper MG; Sgouros G; Hobbs RF
Eur J Nucl Med Mol Imaging; 2018 Jun; 45(6):989-998. PubMed ID: 29460025
[TBL] [Abstract][Full Text] [Related]
18. Targeting Prostate-Specific Membrane Antigen (PSMA) with F-18-Labeled Compounds: the Influence of Prosthetic Groups on Tumor Uptake and Clearance Profile.
Bouvet V; Wuest M; Bailey JJ; Bergman C; Janzen N; Valliant JF; Wuest F
Mol Imaging Biol; 2017 Dec; 19(6):923-932. PubMed ID: 28639122
[TBL] [Abstract][Full Text] [Related]
19.
Liu T; Liu C; Zhang Z; Zhang N; Guo X; Xia L; Jiang J; Xie Q; Yan K; Rowe SP; Zhu H; Yang Z
Eur J Nucl Med Mol Imaging; 2021 Dec; 48(13):4508-4516. PubMed ID: 34170361
[TBL] [Abstract][Full Text] [Related]
20. A microdose clinical trial to evaluate [
Lee I; Lim I; Byun BH; Kim BI; Choi CW; Woo SK; Lee KC; Kang JH; Kil HS; Park C; Chi DY; Park J; Song K; Lim SM
Eur J Nucl Med Mol Imaging; 2021 Jan; 48(1):95-102. PubMed ID: 32458006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
